Algrofin (Crizotinib) is a tyrosine kinase receptor inhibitor which inhibits anaplastic lymphoma kinase (ALK), hepatocyte growth factor receptor (HGFR, c-MET), and Recepteur d’Origine Nantais (RON). Anomalies in the ALK gene caused by mutations or translocations which may lead to expression of oncogenic fusion proteins. Crizotinib inhibits ALK tyrosine kinase which ultimately results in decreased proliferation of cells that carry the genetic mutation and tumors survivability.

Algrofin (Crizotinib INN 250mg Capsule) is a prescription based medicine which is used to treat patients with non-small cell lung cancer (NSCLC) that is caused by a defect in either a gene called ALK (anaplastic lymphoma kinase) or a gene called ROS1.